The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 ...

ENHERTU is a HER2-directed antibody-drug conjugate (ADC) and the FDA approval is based on the results of the registrational Phase II trial DESTINY-Breast01 of ENHERTU (5.4 mg/kg) monotherapy in ...

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

Thousands of women battling advanced breast cancer could be denied access to crucial life-extending medication due to an "unfair" assessment process for NHS drug approval. At such a critical moment in ...

ENHERTU ENHERTU (fam-trastuzumab deruxtecan-nxki in the US only) is a HER2-directed ADC and is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca ...

TOKYO& BASKING RIDGE, N.J.---- The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU ® in combination with rilvegostomig or pembrolizumab versus platinum ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

Enhertu is the second HER2-targeting ADC approved by the US Food and Drug Administration (FDA) after Roche’s Kadcyla (ado-trastuzumab etamine), which was approved in 2013 for HER2-positive (HER2 ...

Enhertu could meet the researchers' goal if the ADC can keep up at its current pace. That said, 5% isn't the most encouraging target, being only slightly better than chemotherapy in this population.